Added to YB: 2026-02-25
Pitch date: 2025-12-15
ELUT [bullish]
Elutia Inc.
+73.25%
current return
Author Info
No bio for this author
Company Info
Elutia Inc., a commercial-stage company, focuses on developing drug-eluting biomatrix products for use in surgical reconstruction and related applications.
Market Cap
$49.2M
Pitch Price
$0.66
Price Target
2.07 (+78%)
Dividend
N/A
EV/EBITDA
-1.01
P/E
-1.80
EV/Sales
1.37
Sector
Biotechnology
Category
special_situation
Elutia Inc. - $ELUT
ELUT: Biologic co sold EluPro to Boston Scientific for $88M, now has $45-50M net cash vs $32.8M mkt cap. Focusing on NXT-41x for breast recon where complication rates are 15-20% (5-7x higher than pacemakers). CEO w/ proven track record (grew Osiris 41x, sold for $660M). 2027 launch. 50% success odds at 10% mkt share = 3x upside; high success scenario = 10x+ potential.
Read full article (4 min)